Drug Reference for FDA Approved General Anesthetics @ Neurotransmitter.net


Advertisement


Generic Name:
desflurane

Trade Name:
Suprane® [Baxter]

IUPAC Name:
2-(difluoromethoxy)-1,1,1,2-tetrafluoro-
ethane


Dosage Forms/Routes:
volatile liquid/inhalation

Major Metabolite:
trifluoroacetic acid

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
09/18/1992


Manufacturers:

[FDA Search]

Prescribing
Information:

[
Link]

RxList:
[
Link]

Empirical Formula:
C3H2F6O

Molecular Mass:
168.038 g/mol

Possible Mechanisms of Action:
Desflurane is a noncompetitive antagonist of NMDA receptor channels (1).
In addition, desflurane increases the effect of GABA at GABA-A receptor channels (2). The drug may also activate the human tandem pore domain potassium channel, TRESK (3). Desflurane may affect other types of potassium channels as well, but more research is necessary to provide a more comprehensive profile of the drug's effects on ion channels. Compared with halothane, desflurane is a relatively weak inducer of Ca2+ release from sarcoplasmic reticulum Ca2+ release channels in muscle cells (4). Nevertheless, the drug should definitely be avoided in all patients susceptible to malignant hyperthermia (5) .

Because the other fluorinated volatile anesthetics enhance the effect of glycine at glycine receptors, desflurane is likely to share this mechanism of action. However, further experimentation is needed in order to clarify the matter. In addition, desflurane is likely to share another key property with other fluorinated anesthetics: the ability to inhibit the exchange of GTPγS for GDP bound to the nucleotide binding site of a subset of Gα proteins that may include Gαq (6).

Indications:
Desflurane is indicated as an inhalation agent for induction and/or maintenance of anesthesia for inpatient and outpatient surgery in adults (see PRECAUTIONS in the prescribing information).

Desflurane is not recommended for induction of anesthesia in pediatric patients because of a high incidence of moderate to severe upper airway adverse events (see WARNINGS in the prescribing information). After induction of anesthesia with agents other than desflurane, and tracheal intubation, desflurane is indicated for maintenance of anesthesia in infants and children.

Chemical Class:
haloether

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link

Generic Name:
enflurane

Trade Name:
Ethrane ® [Baxter]

IUPAC Name:
2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-
ethane


Dosage Forms/Routes:
volatile liquid/inhalation

Major Metabolite:
trifluoroacetic acid

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
08/28/1972


Manufacturers:

[FDA Search]

Prescribing
Information:

[
Link]

Empirical Formula:
C3H2ClF5O

Molecular Mass:
184.492 g/mol

Possible Mechanisms of Action:
Enflurane is a noncompetitive inhibitor of NMDA and AMPA glutamate receptor channels (7, 8). Enflurane enhances the effect of glutamate at GluR6 kainate receptor channels (9, 10). In addition, the drug enhances the effect of glycine at glycine receptor channels and the effect of GABA at GABA-A receptor channels (11). Furthermore, enflurane may inhibit voltage-gated Na+ channels (12).
Enflurane may also inhibit certain types of potassium channels, such as the human intermediate conductance Ca2+ activated K+ channel hIK1 (13). The drug may also have a small inhibitory effect at Kv1.1 voltage-gated K+ channels (14).

At sub-anesthetic doses, enflurane inhibits the exchange of GTPγS for GDP bound to the nucleotide binding site of a subset of Gα (G alpha) proteins; these include Gαi2 > Gαi1 > Gαi3 > Gαs (15).

Enflurane inhibits plasma membrane Ca2+-ATPase and sarcoplasmic reticulum Ca2+-ATPase (16). The drug may also increase the release of Ca2+ from sarcoplasmic reticulum Ca2+ release channels in muscle cells (17). Depending on the cell type considered, enflurane might inhibit T-type and L-type voltage-gated Ca2+ channels (18). The drug may inhibit the effect of GABA at rho1 GABA-C receptors as well (19). Finally, enflurane may enhance the effect of serotonin at 5-HT3 receptor channels (20).

Indications:
Enflurane may be used for induction and maintenance of general anesthesia. Enflurane may be used to provide analgesia for vaginal delivery. Low concentrations of enflurane (see DOSAGE AND ADMINISTRATION in the prescribing information) may also be used to supplement other general anesthetic agents during delivery by Cesarean section. Higher concentrations of enflurane may produce uterine relaxation and an increase in uterine bleeding.

Chemical Class:
haloether

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link

Generic Name:
etomidate

Trade Name:
Amidate® [Hospira]

IUPAC Name:
ethyl 3-(1-phenylethyl)imidazole-4-carboxylate


Dosage Forms/Routes:
injectable/injection

Major Metabolite:
R-(+)-1-(1- phenylethyl)-1H-imidazole-
5-carboxylic acid

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
09/07/1982


Manufacturers:

[FDA Search]

Prescribing
Information:

[
Link] (for generic)

Empirical Formula:
C14H16N2O2

Molecular Mass:
244.289 g/mol

Possible Mechanisms of Action:
Etomidate potentiates the effect of GABA at GABA-A receptor channels (21). At T-type voltage-gated calcium channels, etomidate may have an inhibitory effect (22, 23). Etomidate is also an inhibitor of adrenocortical 11 beta-hydroxylase (24).

Indications:
Etomidate injection is indicated by intravenous injection for the induction of general anesthesia. When considering use of etomidate, the usefulness of its hemodynamic properties (see CLINICAL PHARMACOLOGY in the prescribing information) should be weighed against the high frequency of transient skeletal muscle movements (see ADVERSE REACTIONS in the prescribing information). Intravenous etomidate is also indicated for the supplementation of subpotent anesthetic agents, such as nitrous oxide in oxygen, during maintenance of anesthesia for short operative procedures such as dilation and curettage or cervical conization.

Chemical Class:
carboxylated imidazole

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link

Generic Name:
halothane

IUPAC Name:
2-bromo-2-chloro-1,1,1-trifluoro-ethane


Dosage Forms/Routes:
volatile liquid/inhalation

Major Metabolite:
trifluoroacetic acid

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
03/12/1958


Manufacturers:

[FDA Search]

RxList:
[
Link]

Empirical Formula:
C2HBrClF3

Molecular Mass:
197.381 g/mol

Possible Mechanisms of Action:
Halothane is a noncompetitive antagonist of NMDA receptor channels (25).
In addition, halothane potentiates the effect of GABA at GABA-A receptor channels (26). The drug also potentiates the effect of glycine at glycine receptor channels (27). Halothane may act as an antagonist at glutamate AMPA receptors expressing subunits such as GluR1, GluR3, and GluR2+3, but the drug enhances the effect of glutamate at GluR6 kainate receptor channels (9). Halothane may also potentiate the effect of serotonin at 5-HT3 receptors (28, 29). In addition, the drug is an antagonist at some neuronal nicotinic acetylcholine receptor subtypes such as the alpha7 (29) and alpha4beta2 (30) subtypes.Enflurane might also inhibit the effect of GABA at rho1 GABA-C receptors (19).

Halothane activates human tandem pore domain potassium channels such as TRESK (3), TREK-1 (31), TREK-2 (32), TASK-1 (31, 33), and TASK-3 (33). In addition, halothane may inhibit voltage-gated Na+ channels (12). The drug may also inhibit L-type voltage-gated calcium channels (34). Furthermore, halothane might weakly inhibit T-type voltage-gated calcium channels (35). Halothane also inhibits plasma membrane Ca2+-ATPase and sarcoplasmic reticulum Ca2+-ATPase (16). In skeletal muscle, the drug induces the release of Ca2+ from the sarcoplasmic reticulum Ca2+ release channel, also known as the ryanodine receptor (36).

At sub-anesthetic doses, halothane inhibits the exchange of GTPγS for GDP bound to the nucleotide binding site of a subset of Gα (G alpha) proteins; these include Gαi2 > Gαi1 > Gαi3 > Gαs (15).

Indications:
Halothane is indicated for the induction and maintenance of general anesthesia.

Chemical Class:
haloalkane

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link

Generic Name:
isoflurane

Trade Name:
Forane® [Baxter]

IUPAC Name:
2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-
ethane


Dosage Forms/Routes:
volatile liquid/inhalation

Major Metabolite:
trifluoroacetic acid

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
12/18/1979


Manufacturers:

[FDA Search]

Prescribing
Information:

[
Link]

RxList:
[
Link]

Empirical Formula:
C3H2ClF5O

Molecular Mass:
184.492 g/mol

Possible Mechanisms of Action:
Isoflurane is a noncompetitive antagonist of NMDA receptor channels (1).
In addition, isoflurane potentiates the effect of GABA at GABA-A receptor channels (26). Glycine's effect at glycine receptor channels is also potentiated by isoflurane (37). Isoflurane may weakly inhibit glutamate AMPA receptors expressing subunits such as GluR1, GluR3, and GluR2+3, but the drug enhances the effect of glutamate at GluR6 kainate receptor channels (9). Isoflurane may also potentiate the effect of serotonin at 5-HT3 receptors (28, 29). In addition, the drug is an antagonist at some neuronal nicotinic acetylcholine receptor subtypes such as the alpha7 (29) and alpha4beta2 (30) subtypes. Isoflurane might also inhibit the effect of GABA at rho1 GABA-C receptors (19).

Isoflurane may inhibit voltage-gated Na+ channels (12). The drug may also inhibit L-type voltage-gated calcium channels (34). Isoflurane might also weakly inhibit T-type voltage-gated calcium channels (22, 38). Isoflurane is likely to activate human tandem pore domain potassium channels such as TRESK (3), TREK-1 (31), TREK-2 (32), TASK-1 (31), and TASK-3 (39). Isoflurane also inhibits plasma membrane Ca2+-ATPase and sarcoplasmic reticulum Ca2+-ATPase (16). The drug may also increase the release of Ca2+ from sarcoplasmic reticulum Ca2+ release channels in muscle cells (17).

At sub-anesthetic doses, isoflurane inhibits the exchange of GTPγS for GDP bound to the nucleotide binding site of a subset of Gα (G alpha) proteins; these include Gαi2 > Gαi1 > Gαi3 > Gαs (15).

Indications:
Isoflurane may be used for the induction and maintenance of general anesthesia. Adequate data have not been developed to establish its application in obstetrical anesthesia.

Chemical Class:
haloether

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link

Generic Name:
ketamine hydrochloride

Trade Name:
Ketalar® [Parkedale]

IUPAC Name:
2-(2-chlorophenyl)-2-methylamino-
cyclohexan-1-one hydrochloride


Dosage Forms/Routes:
injectable/injection

Major Metabolites:
norketamine;
hydroxynorketamine

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
02/19/1970


Manufacturers:

[FDA Search]

Prescribing
Information:

[
Link]

RxList:
[
Link]

Empirical Formula:
C13H17Cl2NO

Molecular Mass:
274.186 g/mol

Possible Mechanisms of Action:
Ketamine is a noncompetitive antagonist of NMDA receptor channels (1). The drug also inhibits some subtypes of neuronal nicotinic acetylcholine receptors in a noncompetitive and voltage-dependent manner (40). In addition, ketamine may be an antagonist at muscarinic M1 receptors (41). Further research is needed to clarify whether ketamine affects additional receptors at clinical concentrations.

Indications:
Ketamine hydrochloride injection is indicated as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation.
Ketamine hydrochloride injection is best suited for short procedures but it can be used, with additional doses, for longer procedures.

Ketamine hydrochloride injection is indicated for the induction of anesthesia prior to the administration of other general anesthetic agents.

Ketamine hydrochloride injection is indicated to supplement low-potency agents, such as nitrous oxide.

Specific areas of application are described in the CLINICAL PHARMACOLOGY section of the prescribing information.

Chemical Class:
arylcyclohexylamine

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link

Generic Name:
methohexital

Trade Name:
Brevital® Sodium [King]

IUPAC Name:
1-methyl-5-(1-methylpent-2-ynyl)-5-prop-
2-enyl-hexahydropyrimidine-2,4,6-trione


Dosage Forms/Routes:
injectable/injection

Major Metabolite:
4'-hydroxymethohexital

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
06/27/1960


Manufacturers:

[FDA Search]

Prescribing
Information:

[
Link]

RxList:
[
Link]

Empirical Formula:
C14H17N2NaO3

Molecular Mass:
284.286 g/mol

Possible Mechanisms of Action:
Methohexital potentiates the effect of GABA at GABA-A receptor channels and directly causes the channels to open at higher concentrations (42). Methohexital may also act as an antagonist at kainate glutamate receptors (43, 44). Methohexital is likely to bind to glycine receptors without activating them or blocking glycine's effects; however, the drug may block the effects of thiopental and pentobarbital at glycine receptors (45).

Indications:
Brevital Sodium can be used in adults as follows:

  1. For intravenous induction of anesthesia prior to the use of other general anesthetic agents.
  2. For intravenous induction of anesthesia and as an adjunct to subpotent inhalational anesthetic agents (such as nitrous oxide in oxygen) for short surgical procedures; Brevital Sodium may be given by infusion or intermittent injection.
  3. For use along with other parenteral agents, usually narcotic analgesics, to supplement subpotent inhalational anesthetic agents (such as nitrous oxide in oxygen) for longer surgical procedures.
  4. As intravenous anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli (see WARNINGS in the prescribing information). 5. As an agent for inducing a hypnotic state.

Brevital Sodium can be used in pediatric patients older than 1 month as follows:

  1. For rectal or intramuscular induction of anesthesia prior to the use of other general anesthetic agents.
  2. For rectal or intramuscular induction of anesthesia and as an adjunct to subpotent inhalational anesthetic agents for short surgical procedures.
  3. As rectal or intramuscular anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.

Chemical Class:
barbiturate

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link

Generic Name:
midazolam hydrochloride

IUPAC Name:
8-chloro-6-(2-fluorophenyl)-1-methyl-4H-
Imidazo(1,5-a)(1,4)benzodiazepine

Dosage Forms/Routes:
injectable/injection;
syrup/oral

Major Metabolites:
1-hydroxymidazolam;
4-hydroxymidazolam

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
12/20/1985


Manufacturers:

[FDA Search]

Prescribing
Information:

[
Link] (injectable)
[Link] (syrup)

RxList:
[
Link]

Empirical Formula:
C18H14Cl2FN3

Molecular Mass:
362.228 g/mol

Possible Mechanism of Action:
Midazolam is a water soluble benzodiazepine agonist (46).

Indications:
Midazolam hydrochloride is indicated:

  • intramuscularly or intravenously for preoperative sedation/ anxiolysis/amnesia;
  • intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other CNS depressants;
  • intravenously for induction of general anesthesia, before administration of other anesthetic agents. With the use of narcotic premedication, induction of anesthesia can be attained within a relatively narrow dose range and in a short period of time. Intravenous midazolam can also be used as a component of intravenous supplementation of nitrous oxide and oxygen (balanced anesthesia);
  • continuous intravenous infusion for sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a critical care setting.

Chemical Class:
1,4-imidazole benzodiazepine

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link

Generic Name:
nitrous oxide

IUPAC Name:
dinitrogen oxide


Dosage Forms/Routes:
gas/inhalation

Metabolism:
Nitrous oxide is not metabolized in the body.

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Empirical Formula:
N2O

Molecular Mass:
44.0129 g/mol

Possible Mechanisms of Action:
The key effect of nitrous oxide is its noncompetitive antagonism of NMDA receptor complexes (47). Nitrous oxide also slightly inhibits glutamate AMPA and kainate receptors (47).
The drug is a noncompetitive antagonist at some subtypes of neuronal nicotinic acetylcholine receptors such as the alpha4beta2 subtype (47). Nitrous oxide weakly potentiates the effect of GABA at GABA-A receptor channels, but this effect may not be relevant at clinical concentrations (47). In addition, the drug might inhibit the effect of GABA at rho1 GABA-C receptors (47). Glycine's effects at glycine receptor channels may be slightly potentiated by nitrous oxide (47). Nitrous oxide may slightly inhibit serotonin 5-HT3 receptors in a competitive manner (28, 47). The drug might also inhibit T-type voltage-gated calcium channels as well (48). Finally, nitrous oxide activates TREK-1, a two pore-domain potassium channel (49).

Nitrous oxide increases the production of nitric oxide (NO) via the neuronal isoform of nitric oxide synthase (nNOS) (50). Nitrous oxide- induced NO production may lead to the neuronal release of endogenous opioid peptides (50).

Indications:
Nitrous oxide is indicated for the induction and maintenance of sedation. In addition, it is approved for the induction and maintenance of general anesthesia. However, nitrous oxide is rarely used alone; other medications are frequently administered to induce or supplement anesthesia. Because of its weak anesthetic potency and muscle relaxant properties, nitrous oxide must be supplemented with another anesthetic or anesthesia adjunct (such as a barbiturate, benzodiazepine, opioid analgesic, or another inhalation anesthetic) and/or a neuromuscular blocking agent. Also, nitrous oxide is often administered concurrently with one of the other inhalation anesthetics to decrease the requirement for the more potent anesthetic.

Chemical Class:
inorganic nitrogen compound

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link

Generic Name:
propofol

Trade Name:
Diprivan® [Abraxis]

IUPAC Name:
2,6-dipropan-2-ylphenol


Dosage Forms/Routes:
injectable/injection

Major Metabolites:
propofol-glucuronide;
4-(2,6-diisopropyl-1,4-quinol)-sulphate;
1-(2,6-diisopropyl-1,4-quinol)-glucuronide;
4-(2,6-diisopropyl-1,4-quinol)-glucuronide

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
10/02/1989


Manufacturers:

[FDA Search]

Prescribing
Information:

[
Link]

RxList:
[
Link]

Empirical Formula:
C12H18O

Molecular Mass:
178.271 g/mol

Possible Mechanisms of Action:
Propofol potentiates the effects of GABA at GABA-A receptors and glycine at glycine receptors (51). At higher concentrations, propofol directly causes both GABA-A and glycine receptor channels to open (51). Propofol may also inhibit and slow the activation of hyperpolarization-activated, cyclic nucleotide-gated channels such as HCN1, HCN2, and HCN4 (52).

In addition, propofol may have a small but significant inhibitory effect on voltage-dependent Na+ channels (12). Propofol may also inhibit T-type voltage-gated calcium channels (22, 23). Finally, propofol is an inhibitor of fatty acid amide hydrolase (53).

Indications:
Propofol is an IV sedative-hypnotic agent that can be used for both induction and/or maintenance of anesthesia as proof of a balanced anesthetic technique for inpatient and outpatient surgery in adults and in children 3 years of age or older.

Propofol, when administered intravenously as directed, can be used to initiate and maintain monitored anesthesia care (MAC) sedation during diagnostic procedures in adults. Propofol may also be used for MAC sedation in conjunction with local/regional anesthesia in patients undergoing surgical procedures. (See PRECAUTIONS in the prescribing information).

Propofol should only be administered to intubated, mechanically ventilated adult patients in the Intensive Care Unit (ICU) to provide continuous sedation and control of stress responses. In this setting, propofol should be administered only by persons skilled in the medical management of critically ill patients and trained in cardiovascular resuscitation and airway management.

Chemical Class:
phenol derivative

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link

Generic Name:
sevoflurane

Trade Name:
Ultane ® [Abbott]

IUPAC Name:
1,1,1,3,3,3-hexafluoro-2-
(fluoromethoxy)propane


Dosage Forms/Routes:
volatile liquid/inhalation

Major Metabolite:
hexafluoroisopropanol

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
06/07/1995


Manufacturers:

[FDA Search]

Prescribing
Information:

[
Link]

RxList:
[
Link]

Empirical Formula:
C4H3F7O

Molecular Mass:
200.055 g/mol

Possible Mechanisms of Action:
Sevoflurane is a noncompetitive antagonist of NMDA receptor channels (1). In addition, sevoflurane enhances the effect of GABA at GABA-A receptor channels (2).
Glycine's effect at glycine receptor channels is also potentiated by sevoflurane (37). Sevoflurane may weakly inhibit glutamate AMPA receptors, and more research is necessary to better characterize its effects at these receptors (54). Sevoflurane is also a noncompetitive antagonist at serotonin 5-HT3 receptors (28). In addition, the drug is likely to be an antagonist at some neuronal nicotinic acetylcholine receptor subtypes such as the alpha4beta2 (30) subtype.

Sevoflurane may inhibit voltage-gated Na+ channels (55). The drug may also inhibit L-type voltage-gated calcium channels (56). Sevoflurane might inhibit T-type voltage-gated calcium channels as well (57). In skeletal muscle, sevoflurane induces the release of Ca2+ from the sarcoplasmic reticulum Ca2+ release channel, also known as the ryanodine receptor (36). Furthermore, sevoflurane is a potent activator of the human tandem pore domain potassium channel, TRESK (3). The drug is also likely to activate the human tandem pore domain potassium channel TASK-1 (58).

At sub-anesthetic doses, sevoflurane inhibits the exchange of GTPγS for GDP bound to the nucleotide binding site of a subset of Gα (G alpha) proteins; these include Gαi2 > Gαi1 > Gαi3 > Gαs (15).

Indications:
Sevoflurane is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.

Sevoflurane should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane should be used.

Chemical Class:
haloether

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link

Generic Name:
thiopental sodium

Trade Name:
Pentothal ® [Hospira]

IUPAC Name:
sodium 5-ethyl-6-oxo-5-pentan-2-
yl-2-sulfanylidene-pyrimidin-4-olate


Dosage Forms/Routes:
injectable/injection [the drug is prepared as a sterile powder and after reconstitution with an appropriate diluent is administered by the intravenous route]

Major Metabolite:
pentobarbital

Database Search Links:
[PubMed]
[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
1959


Manufacturers:

[FDA Search]

Prescribing
Information:

[
Link]

RxList:
[
Link]

Empirical Formula:
C11H17N2NaO2S

Molecular Mass:
264.321 g/mol

Possible Mechanisms of Action:
Thiopental potentiates the effect of GABA at GABA-A receptor channels (59). The drug also potentiates the effect of glycine at glycine receptor channels (27). Furthermore, thiopental may potently inhibit voltage-gated calcium channels and weakly inhibit NMDA glutamate receptor channels (60). Thiopental may also inhibit neuronal nicotinic acetylcholine receptors (61).

Indications:
Pentothal (Thiopental Sodium for Injection, USP) is indicated (1) as the sole anesthetic agent for brief (15 minute) procedures, (2) for induction of anesthesia prior to administration of other anesthetic agents, (3) to supplement regional anesthesia, (4) to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation, (5) for the control of convulsive states during or following inhalation anesthesia, local anesthesia, or other causes, (6) in neurosurgical patients with increased intracranial pressure, if adequate ventilation is provided, and (7) for narcoanalysis and narcosynthesis in psychiatric disorders.

Chemical Class:
thiobarbiturate

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link

References:

1. Hollmann MW, Liu HT, Hoenemann CW, Liu WH, Durieux ME
Modulation of NMDA receptor function by ketamine and magnesium. Part II: interactions with volatile anesthetics.
Anesth Analg. 2001 May;92(5):1182-91. [Full Text]

2. Nishikawa K, Harrison NL
The actions of sevoflurane and desflurane on the gamma-aminobutyric acid receptor type A: effects of TM2 mutations in the alpha and beta subunits.
Anesthesiology. 2003 Sep;99(3):678-84. [Abstract]

3. Liu C, Au JD, Zou HL, Cotten JF, Yost CS
Potent activation of the human tandem pore domain K channel TRESK with clinical concentrations of volatile anesthetics.
Anesth Analg. 2004 Dec;99(6):1715-22, table of contents. [Full Text]


4. Kunst G, Stucke AG, Graf BM, Martin E, Fink RH
Desflurane induces only minor Ca2+ release from the sarcoplasmic reticulum of mammalian skeletal muscle.
Anesthesiology. 2000 Sep;93(3):832-6. [Abstract]

5. Wappler F, Fiege M
Is desflurane a "weak" trigger of malignant hyperthermia?
Anesth Analg. 2003 Jul;97(1):295; author reply 295. [Full Text]

6. Nakayama T, Penheiter AR, Penheiter SG, Chini EN, Thompson M, Warner DO, Jones KA
Differential effects of volatile anesthetics on M3 muscarinic receptor coupling to the Galphaq heterotrimeric G protein.
Anesthesiology. 2006 Aug;105(2):313-24. [Abstract]

7. Lin LH, Chen LL, Harris RA
Enflurane inhibits NMDA, AMPA, and kainate-induced currents in Xenopus oocytes expressing mouse and human brain mRNA.
FASEB J. 1993 Mar;7(5):479-85. [Full Text]

8. Cheng G, Kendig JJ
Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors.
Anesthesiology. 2000 Oct;93(4):1075-84. [Abstract]

9. Dildy-Mayfield JE, Eger EI, Harris RA
Anesthetics produce subunit-selective actions on glutamate receptors.
J Pharmacol Exp Ther. 1996 Mar;276(3):1058-65. [Abstract]

10. Minami K, Wick MJ, Stern-Bach Y, Dildy-Mayfield JE, Brozowski SJ, Gonzales EL, Trudell JR, Harris RA
Sites of volatile anesthetic action on kainate (Glutamate receptor 6) receptors.
J Biol Chem. 1998 Apr 3;273(14):8248-55. [Full Text]

11. Mihic SJ, Ye Q, Wick MJ, Koltchine VV, Krasowski MD, Finn SE, Mascia MP, Valenzuela CF, Hanson KK, Greenblatt EP, Harris RA, Harrison NL
Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors.
Nature. 1997 Sep 25;389(6649):385-9. [Abstract]

12. Lingamaneni R, Hemmings HC
Differential interaction of anaesthetics and antiepileptic drugs with neuronal Na+ channels, Ca2+ channels, and GABA(A) receptors.
Br J Anaesth. 2003 Feb;90(2):199-211. [Full Text]

13. Namba T, Ishii TM, Ikeda M, Hisano T, Itoh T, Hirota K, Adelman JP, Fukuda K
Inhibition of the human intermediate conductance Ca(2+)-activated K(+) channel, hIK1, by volatile anesthetics.
Eur J Pharmacol. 2000 Apr 28;395(2):95-101. [Abstract]

14. Friederich P, Benzenberg D, Trellakis S, Urban BW
Interaction of volatile anesthetics with human Kv channels in relation to clinical concentrations.
Anesthesiology. 2001 Oct;95(4):954-8. [Abstract]

15. Pentyala SN, Sung K, Chowdhury A, Rebecchi MJ
Volatile anesthetics modulate the binding of guanine nucleotides to the alpha subunits of heterotrimeric GTP binding proteins.
Eur J Pharmacol. 1999 Nov 19;384(2-3):213-22. [Abstract]

16. Lopez MM, Kosk-Kosicka D
How do volatile anesthetics inhibit Ca(2+)-ATPases?
J Biol Chem. 1995 Nov 24;270(47):28239-45. [Abstract]

17. Louis CF, Zualkernan K, Roghair T, Mickelson JR
The effects of volatile anesthetics on calcium regulation by malignant hyperthermia-susceptible sarcoplasmic reticulum.
Anesthesiology. 1992 Jul;77(1):114-25. [Abstract]

18. McDowell TS, Pancrazio JJ, Lynch C
Volatile anesthetics reduce low-voltage-activated calcium currents in a thyroid C-cell line.
Anesthesiology. 1996 Nov;85(5):1167-75. [Abstract]

19. Mihic SJ, Harris RA
Inhibition of rho1 receptor GABAergic currents by alcohols and volatile anesthetics.
J Pharmacol Exp Ther. 1996 Apr;277(1):411-6. [Abstract]

20. Lopreato GF, Banerjee P, Mihic SJ
Amino acids in transmembrane domain two influence anesthetic enhancement of serotonin-3A receptor function.
Brain Res Mol Brain Res. 2003 Oct 21;118(1-2):45-51. [Abstract]

21. Yang J, Uchida I
Mechanisms of etomidate potentiation of GABAA receptor-gated currents in cultured postnatal hippocampal neurons.
Neuroscience. 1996 Jul;73(1):69-78. [Abstract]

22. Todorovic SM, Perez-Reyes E, Lingle CJ
Anticonvulsants but not general anesthetics have differential blocking effects on different T-type current variants.
Mol Pharmacol. 2000 Jul;58(1):98-108. [Full Text]

23. Joksovic PM, Brimelow BC, Murbartián J, Perez-Reyes E, Todorovic SM
Contrasting anesthetic sensitivities of T-type Ca2+ channels of reticular thalamic neurons and recombinant Ca(v)3.3 channels.
Br J Pharmacol. 2005 Jan;144(1):59-70. [Full Text]

24.Allolio B, Dörr H, Stuttmann R, Knorr D, Engelhardt D, Winkelmann W
Effect of a single bolus of etomidate upon eight major corticosteroid hormones and plasma ACTH.
Clin Endocrinol (Oxf). 1985 Mar;22(3):281-6. [Abstract]

25.Ogata J, Shiraishi M, Namba T, Smothers CT, Woodward JJ, Harris RA
Effects of anesthetics on mutant N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
J Pharmacol Exp Ther. 2006 Jul;318(1):434-43. [Abstract]

26. Nishikawa K, Jenkins A, Paraskevakis I, Harrison NL
Volatile anesthetic actions on the GABAA receptors: contrasting effects of alpha 1(S270) and beta 2(N265) point mutations.
Neuropharmacology. 2002 Mar;42(3):337-45. [Abstract]

27. Daniels S, Roberts RJ
Post-synaptic inhibitory mechanisms of anaesthesia; glycine receptors.
Toxicol Lett. 1998 Nov 23;100-101:71-6. [Abstract]

28. Suzuki T, Koyama H, Sugimoto M, Uchida I, Mashimo T
The diverse actions of volatile and gaseous anesthetics on human-cloned 5-hydroxytryptamine3 receptors expressed in Xenopus oocytes.
Anesthesiology. 2002 Mar;96(3):699-704. [Abstract]

29. Zhang L, Oz M, Stewart RR, Peoples RW, Weight FF
Volatile general anaesthetic actions on recombinant nACh alpha 7, 5-HT3 and chimeric nACh alpha 7-5-HT3 receptors expressed in Xenopus oocytes.
Br J Pharmacol. 1997 Feb;120(3):353-5. [Full Text]

30. Yamashita M, Mori T, Nagata K, Yeh JZ, Narahashi T
Isoflurane modulation of neuronal nicotinic acetylcholine receptors expressed in human embryonic kidney cells.
Anesthesiology. 2005 Jan;102(1):76-84. [Abstract]

31. Patel AJ, Honoré E, Lesage F, Fink M, Romey G, Lazdunski M
Inhalational anesthetics activate two-pore-domain background K+ channels.
Nat Neurosci. 1999 May;2(5):422-6. [Full Text]

32. Lesage F, Terrenoire C, Romey G, Lazdunski M
Human TREK2, a 2P domain mechano-sensitive K+ channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and Gs, Gi, and Gq protein-coupled receptors.
J Biol Chem. 2000 Sep 15;275(37):28398-405. [Full Text]

33. Talley EM, Bayliss DA
Modulation of TASK-1 (Kcnk3) and TASK-3 (Kcnk9) potassium channels: volatile anesthetics and neurotransmitters share a molecular site of action.
J Biol Chem. 2002 May 17;277(20):17733-42. [Full Text]

34. Kamatchi GL, Durieux ME, Lynch C
Differential sensitivity of expressed L-type calcium channels and muscarinic M(1) receptors to volatile anesthetics in Xenopus oocytes.
J Pharmacol Exp Ther. 2001 Jun;297(3):981-90. [Full Text]

35. McDowell TS, Pancrazio JJ, Barrett PQ, Lynch C
Volatile anesthetic sensitivity of T-type calcium currents in various cell types.
Anesth Analg. 1999 Jan;88(1):168-73. [Full Text]

36. Duke AM, Hopkins PM, Halsall PJ, Steele DS
Mg2+ dependence of Ca2+ release from the sarcoplasmic reticulum induced by sevoflurane or halothane in skeletal muscle from humans susceptible to malignant hyperthermia.
Br J Anaesth. 2006 Sep;97(3):320-8. [Abstract]

37. Downie DL, Hall AC, Lieb WR, Franks NP
Effects of inhalational general anaesthetics on native glycine receptors in rat medullary neurones and recombinant glycine receptors in Xenopus oocytes.
Br J Pharmacol. 1996 Jun;118(3):493-502. [Abstract]

38.
McDowell TS, Pancrazio JJ, Barrett PQ, Lynch C
Volatile anesthetic sensitivity of T-type calcium currents in various cell types.
Anesth Analg. 1999 Jan;88(1):168-73. [Full Text]

39. Liu C, Cotten JF, Schuyler JA, Fahlman CS, Au JD, Bickler PE, Yost CS
Protective effects of TASK-3 (KCNK9) and related 2P K channels during cellular stress.
Brain Res. 2005 Jan 21;1031(2):164-73. [Abstract]

40. Yamakura T, Chavez-Noriega LE, Harris RA.
Subunit-dependent inhibition of human neuronal nicotinic acetylcholine receptors and other ligand-gated ion channels by dissociative anesthetics ketamine and dizocilpine.
Anesthesiology 2000 Apr;92(4):1144-53 [Abstract]

41. Durieux ME.
Inhibition by ketamine of muscarinic acetylcholine receptor function.
Anesth Analg 1995 Jul;81(1):57-62 [Abstract]

42. Koltchine VV, Ye Q, Finn SE, Harrison NL
Chimeric GABAA/glycine receptors: expression and barbiturate pharmacology.
Neuropharmacology. 1996;35(9-10):1445-56. [Abstract]

43. Zeman S, Lodge D
Pharmacological characterization of non-NMDA subtypes of glutamate receptor in the neonatal rat hemisected spinal cord in vitro.
Br J Pharmacol. 1992 Jun;106(2):367-72. [Abstract]

44. Palmer AJ, Zeman S, Lodge D
Methohexitone antagonises kainate and epileptiform activity in rat neocortical slices.
Eur J Pharmacol. 1992 Oct 20;221(2-3):205-9. [Abstract]

45. Hadipour-Jahromy M, Daniels S
Binary combinations of propofol and barbiturates on human alpha(1) glycine receptors expressed in Xenopus oocytes.
Eur J Pharmacol. 2003 Sep 12;477(2):81-6. [Abstract]

46. Reves JG, Corssen G, Holcomb C
Comparison of two benzodiazepines for anaesthesia induction: midazolam and diazepam.
Can Anaesth Soc J. 1978 May;25(3):211-4. [Abstract]

47. Yamakura T, Harris RA
Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol.
Anesthesiology. 2000 Oct;93(4):1095-101. [Abstract]

48. Todorovic SM, Jevtovic-Todorovic V, Mennerick S, Perez-Reyes E, Zorumski CF
Ca(v)3.2 channel is a molecular substrate for inhibition of T-type calcium currents in rat sensory neurons by nitrous oxide.
Mol Pharmacol. 2001 Sep;60(3):603-10. [Full Text]

49. Gruss M, Bushell TJ, Bright DP, Lieb WR, Mathie A, Franks NP
Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane.
Mol Pharmacol. 2004 Feb;65(2):443-52. [Full Text]

50.
Li S, Bieber AJ, Quock RM
Antagonism of nitrous oxide antinociception in mice by antisense oligodeoxynucleotide directed against neuronal nitric oxide synthase enzyme.
Behav Brain Res. 2004 Jul 9;152(2):361-3. [Abstract]

51. Pistis M, Belelli D, Peters JA, Lambert JJ
The interaction of general anaesthetics with recombinant GABAA and glycine receptors expressed in Xenopus laevis oocytes: a comparative study.
Br J Pharmacol. 1997 Dec;122(8):1707-19. [Full Text]

52. Cacheaux LP, Topf N, Tibbs GR, Schaefer UR, Levi R, Harrison NL, Abbott GW, Goldstein PA
Impairment of hyperpolarization-activated, cyclic nucleotide-gated channel function by the intravenous general anesthetic propofol.
J Pharmacol Exp Ther. 2005 Nov;315(2):517-25. [Full Text]

53. Patel S, Wohlfeil ER, Rademacher DJ, Carrier EJ, Perry LJ, Kundu A, Falck JR, Nithipatikom K, Campbell WB, Hillard CJ
The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase.
Br J Pharmacol. 2003 Jul;139(5):1005-13. [Full Text]

54. Matute E, Lopez-Garcia JA
Characterisation of sevoflurane effects on spinal somato-motor nociceptive and non-nociceptive transmission in neonatal rat spinal cord: an electrophysiological study in vitro.
Neuropharmacology. 2003 May;44(6):811-6. [Abstract]

55. Burke D, Bartley K, Woodforth IJ, Yakoubi A, Stephen JP
The effects of a volatile anaesthetic on the excitability of human corticospinal axons.
Brain. 2000 May;123 ( Pt 5):992-1000. [Full Text]

56. Fassl J, Halaszovich CR, Hüneke R, Jüngling E, Rossaint R, Lückhoff A
Effects of inhalational anesthetics on L-type Ca2+ currents in human atrial cardiomyocytes during beta-adrenergic stimulation.
Anesthesiology. 2003 Jul;99(1):90-6. [Abstract]

57. Joksovic PM, Bayliss DA, Todorovic SM
Different kinetic properties of two T-type Ca2+ currents of rat reticular thalamic neurones and their modulation by enflurane.
J Physiol. 2005 Jul 1;566(Pt 1):125-42. [Full Text]

58. Sirois JE, Lei Q, Talley EM, Lynch C, Bayliss DA
The TASK-1 two-pore domain K+ channel is a molecular substrate for neuronal effects of inhalation anesthetics.
J Neurosci. 2000 Sep 1;20(17):6347-54. [Full Text]

59. Cordato DJ, Chebib M, Mather LE, Herkes GK, Johnston GA
Stereoselective interaction of thiopentone enantiomers with the GABA(A) receptor.
Br J Pharmacol. 1999 Sep;128(1):77-82. [Full Text]

60. Zhan RZ, Fujiwara N, Yamakura T, Taga K, Fukuda S, Shimoji K
Differential inhibitory effects of thiopental, thiamylal and phenobarbital on both voltage-gated calcium channels and NMDA receptors in rat hippocampal slices.
Br J Anaesth. 1998 Dec;81(6):932-9. [Full Text]

61. Downie DL, Franks NP, Lieb WR
Effects of thiopental and its optical isomers on nicotinic acetylcholine receptors.
Anesthesiology. 2000 Sep;93(3):774-83. [Abstract]